CULLINAN THERAPEUTICS, INC. Operating Expenses
CULLINAN THERAPEUTICS, INC. (CGEM) reported Operating Expenses of $57.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $57.25M, a 24.47% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $53.70M, a 2.36% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $55.26M, a 0.38% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $55.59M, a 13.80% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. operating expenses for fiscal 2025 was $241.65M, a 22.71% increase from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. operating expenses for fiscal 2024 was $196.92M, a 3.29% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. operating expenses for fiscal 2023 was $190.65M, a 44.28% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. operating expenses for fiscal 2022 was $132.14M, a 52.06% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $57.25M 10-Q · filed 2026-08-06 | $110.95M 10-Q · filed 2026-08-06 | $166.21M derived: sum of 3 quarters · filed 2026-08-06 | $221.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $53.70M 10-Q · filed 2026-05-07 | $108.96M derived: sum of 2 quarters · filed 2026-05-07 | $164.55M derived: sum of 3 quarters · filed 2026-05-07 | $240.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $55.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $110.85M derived: sum of 2 quarters · filed 2026-03-10 | $186.65M derived: sum of 3 quarters · filed 2026-08-06 | $241.65M 10-K · filed 2026-03-10 |
| 2025-09-30 | $55.59M 10-Q · filed 2025-11-06 | $131.39M derived: sum of 2 quarters · filed 2026-08-06 | $186.39M 10-Q · filed 2025-11-06 | $241.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $75.80M 10-Q · filed 2026-08-06 | $130.79M 10-Q · filed 2026-08-06 | $185.84M derived: sum of 3 quarters · filed 2026-08-06 | $234.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $55.00M 10-Q · filed 2026-05-07 | $110.04M derived: sum of 2 quarters · filed 2026-05-07 | $158.90M derived: sum of 3 quarters · filed 2026-05-07 | $208.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $55.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $103.90M derived: sum of 2 quarters · filed 2026-03-10 | $153.93M derived: sum of 3 quarters · filed 2026-03-10 | $196.92M 10-K · filed 2026-03-10 |
| 2024-09-30 | $48.85M 10-Q · filed 2025-11-06 | $98.88M derived: sum of 2 quarters · filed 2025-11-06 | $141.87M 10-Q · filed 2025-11-06 | $187.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $50.03M 10-Q · filed 2025-08-07 | $93.02M 10-Q · filed 2025-08-07 | $138.50M derived: sum of 3 quarters · filed 2025-08-07 | $183.30M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $42.99M 10-Q · filed 2025-05-08 | $88.47M derived: sum of 2 quarters · filed 2025-05-08 | $133.28M derived: sum of 3 quarters · filed 2025-05-08 | $170.88M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $45.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $90.29M derived: sum of 2 quarters · filed 2025-02-27 | $127.89M derived: sum of 3 quarters · filed 2025-02-27 | $190.65M 10-K · filed 2025-02-27 |
| 2023-09-30 | $44.80M 10-Q · filed 2024-11-07 | $82.41M derived: sum of 2 quarters · filed 2024-11-07 | $145.16M 10-Q · filed 2024-11-07 | $177.77M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $37.60M 10-Q · filed 2024-08-08 | $100.36M 10-Q · filed 2024-08-08 | $132.97M derived: sum of 3 quarters · filed 2024-08-08 | $162.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $62.76M 10-Q · filed 2024-05-15 | $95.36M derived: sum of 2 quarters · filed 2024-05-15 | $125.13M derived: sum of 3 quarters · filed 2024-05-15 | $162.24M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $62.37M derived: sum of 2 quarters · filed 2024-03-14 | $99.48M derived: sum of 3 quarters · filed 2024-03-14 | $132.14M 10-K · filed 2024-03-14 |
| 2022-09-30 | $29.77M 10-Q · filed 2023-11-08 | $66.87M derived: sum of 2 quarters · filed 2023-11-08 | $99.53M 10-Q · filed 2023-11-08 | $133.88M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $37.11M 10-Q · filed 2023-08-10 | $69.76M 10-Q · filed 2023-08-10 | $104.11M derived: sum of 3 quarters · filed 2023-08-10 | $122.48M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $32.66M 10-Q · filed 2023-05-11 | $67.00M derived: sum of 2 quarters · filed 2023-05-11 | $85.38M derived: sum of 3 quarters · filed 2023-05-11 | $101.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $34.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $52.72M derived: sum of 2 quarters · filed 2023-03-09 | $69.33M derived: sum of 3 quarters · filed 2023-03-09 | $86.90M 10-K · filed 2023-03-09 |
| 2021-09-30 | $18.38M 10-Q · filed 2022-11-14 | $34.98M derived: sum of 2 quarters · filed 2022-11-14 | $52.55M 10-Q · filed 2022-11-14 | $81.72M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $16.60M 10-Q · filed 2022-08-10 | $34.17M 10-Q · filed 2022-08-10 | $63.35M derived: sum of 3 quarters · filed 2022-08-10 | $74.85M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $17.57M 10-Q · filed 2022-05-16 | $46.74M derived: sum of 2 quarters · filed 2022-05-16 | $58.24M derived: sum of 3 quarters · filed 2022-05-16 | $72.36M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $29.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $40.67M derived: sum of 2 quarters · filed 2022-03-17 | $54.79M derived: sum of 3 quarters · filed 2022-03-17 | $60.34M 10-K · filed 2022-03-17 |
| 2020-09-30 | $11.50M 10-Q · filed 2021-11-09 | $25.62M derived: sum of 2 quarters · filed 2021-11-09 | $31.16M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $14.12M 10-Q · filed 2021-08-10 | $19.66M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $5.54M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |